Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin

Abstract: One of the most feared repercussions of type 2 diabetes mellitus is the risk of adverse cardiovascular outcomes. The current antidiabetic agents on the market have had difficulty in showing cardiovascular outcome improvement. The EMPA-REG OUTCOME trial studied the sodium-glucose cotransporter 2 inhibitor empagliflozin in type 2 diabetic patients at high risk of cardiovascular events. The trial results revealed a decrease in the composite primary end points of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in those taking empagliflozin vs placebo. Those taking the medication also had a significant decrease in death from any cause, death from cardiovascular cause, and hospitalization for heart failure. The EMPA-REG trial is paradigm shifting because it demonstrates a clear mortality benefit to cardiovascular outcomes with a low side-effect profile, in contrast to prior outcome studies of hypoglycemic agents. Further studies are required to better clarify the long-term safety and efficacy of this promising class of diabetic drugs.

Keywords: SGLT2 inhibitors, diabetes, cardiovascular mortality, heart failure, hypertension

Introduction

Increased risk of cardiovascular outcomes is a known complication of diabetes mellitus. The current literature on cardiovascular event rates in type 2 diabetic patients is summarized as follows. The “Look AHEAD” trial enrolled 5,145 overweight or obese patients with type 2 diabetes to an intensive lifestyle intervention and had a primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction (MI), nonfatal stroke, or hospitalization for angina during a maximum follow-up of 13.5 years (median follow-up 9.6 years). 1 The trial concluded that an intensive lifestyle intervention focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults with type 2 diabetes. Moreover, the trial highlighted the contemporary cardiovascular (CV) event rates in patients with type 2 diabetes. The macrovascular event rate in type 2 diabetic patients was found to be on par with being a cardiovascular disease risk equivalent (~20% at 10 years). Many large randomized control trials (RCTs), such as the UKPDS study, have demonstrated a significant reduction in microvascular events in patients treated with hypoglycemic agents leading to a reduced hemoglobin A1c. 2 However, on review of the current large safety trials using hypoglycemic agents, the impact on CV event rate has been rare.

Cardiovascular outcome trials for antiglycemic medications have been abundant in recent years. This may be in part due to an US FDA mandate released in 2008 which stated that cardiovascular safety could be assessed in new antidiabetic
therapies before and after FDA approval.\(^3\)\(^4\) This was largely a reaction to the PROACTIVE trial, which was a large RCT that evaluated cardiovascular outcomes in the PPAR\(\gamma\) agonist pioglitazone vs placebo in high-risk individuals.\(^5\) The results demonstrate a statistically significant increase in heart failure events, which largely overshadowed the positive findings that showed significant decrease in the “main” secondary outcome composite of death from any cause, MI (excluding silent MI), and CVA accident in the treatment group. Prior to PROACTIVE trial, metformin was shown to have cardiovascular benefits in patients with newly diagnosed type 2 diabetes in the UKPDS trial; however, this benefit was only shown in a small subgroup of overweight individuals and, in fact, increased mortality was noted in those concurrently taking sulfonylurea.\(^6\) Table 1 summarizes the selected large RCTs on oral hypoglycemic agents and their impact on CV outcomes, including the EMPA-REG study.

In contrast, the sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel group of diabetes medications that offer a revolutionary significant reduction in hospitalization for heart failure and cardiovascular morbidity and mortality (Figure 1). In this review, we highlight the mechanism of action and cardiovascular benefits of SGLT2 inhibitors, particularly empagliflozin.

### SGLT2 inhibitors

SGLTs are a group of proteins that facilitate glucose diffusion across the cell membrane and participate in glucose homeostasis. SGLT1 and SGLT2 are carrier membrane

---

**Table 1 Relevant major CV outcome studies with oral hypoglycemics**

<table>
<thead>
<tr>
<th>Trial</th>
<th>Details</th>
<th>Results</th>
<th>Comments</th>
</tr>
</thead>
</table>
| UKPDS\(^4\) | • N=4,075 patients with DM  
• Primary end point  
  ○ Death  
  ○ All-cause mortality  
  ○ DM-related end point  
• Secondary end point  
  ○ MI, CVA, PVD, microvascular events  
  ○ Nonoverweight patients randomized to either intensive therapy with sulfonylurea, insulin, or diet  
• Subset of 342 overweight patients randomized to metformin, intensive therapy with a sulfonylurea, or insulin. | • Improvement in microvascular events but no improvement in macrovascular events in nonoverweight patients  
• In the overweight subgroup, metformin  
  ○ Reduced all-cause mortality 36% (9–55, \(P=0.011\))  
  ○ Reduced diabetes-related death 42% (9–63, \(P=0.017\))  
  Risk reductions of 32% (95% CI: 13–47, \(P=0.002\)) for any diabetes-related end point. | • Increased mortality in a subgroup of patients given metformin and sulfonylurea. |
| PROACTIVE\(^5\) | • N=5,238 patients with type 2 DM and macrovascular disease (MI or CVA within 6 mo, PCI or CABG within 6 mo or objective evidence of CAD or PVD).  
• Randomized to pioglitazone or placebo  
• Primary end point  
  ○ All-cause mortality, nonfatal MI, CVA, ACS, vascular intervention, or amputation  
• Secondary end point  
  ○ Death from any cause, MI (excluding silent MI), and CVA. | • Significant decrease in the secondary outcome in pioglitazone vs placebo 301 vs 358; HR 0.84; CI: 0.72–0.98; \(P=0.027\). | • Statistically significant increase in heart failure events (417 vs 302; \(P<0.00001\)) in the treatment group. |
| EMPA-REG OUTCOME\(^6\) | • N=7,020 patients with cardiovascular disease to either empagliflozin or placebo  
• Primary outcome  
  ○ Death from cardiovascular causes, nonfatal MI, (excluding silent MI), or nonfatal stroke.  
• Secondary outcome  
  ○ Composite of the primary outcome plus hospitalization for unstable angina. | • Reduction in primary composite outcome at 10.5% vs 12.1%, HR 0.86, CI: 0.74–0.99, \(P=0.04\)  
• Reduction in CV death 3.7% vs 5.9%, HR 0.62, CI: 0.49–0.77, \(P<0.001\)  
• Reduced all-cause mortality 5.7% vs 8.3%, HR 0.68, CI: 0.57–0.82, \(P<0.001\)  
• Reduced hospitalizations for heart failure 2.7% vs 4.1%, HR 0.65, CI: 0.50–0.85  
• Reduction in weight, waist circumference, and systolic blood pressure. | • Increased genital infections (6.4% vs 1.8%; \(P<0.001\)). |

**Abbreviations:** ACS, acute coronary syndrome; CV, cardiovascular; DM, diabetes mellitus; MI, myocardial infarction; CVA, cardiovascular accident; mo, months; CAD, coronary artery disease; HR, hazard ratio; CI, confidence interval; PVD, peripheral vascular disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graph.
Differential cardiovascular profiles of SGLT2 inhibitors

Transporters that couple glucose transport against its concentration gradient into renal tubular epithelial cell with sodium influx across cell membrane down its electrochemical gradient. SGLT2 carrier proteins are predominantly concentrated in the kidney, especially on the epithelial cells of luminal membranes of S1/S2 segment in the proximal convoluted tubule. 

Under normal circumstances, SGLT2 is a low glucose affinity, high-capacity carrier protein that is highly selective for glucose and has a more potent role in renal glucose reabsorption compared to SGLT1. SGLT2-mediated glucose transport is responsible for reabsorption of ~97% of glomerular filtrate. Studies in human and animal models demonstrate that there is substantial upregulation of SGLT2 mRNA and protein expression in epithelial cells of the proximal tubule in chronically hyperglycemic states. This maladaptive response to hyperglycemia causes greater renal reabsorption of glucose and has important implications in patients with diabetes. As a result, SGLT2 inhibition is a vital therapeutic target in diabetes and has led to the approval of several novel SGLT2 inhibitors, which are named glifoxins.

To date, three SGLT2 inhibitors have been FDA approved in US: canagliflozin, dapagliflozin, and empagliflozin. Similarly, ipragliflozin, tofogliflozin, and luseogliflozin are approved in Japan with several other agents in development. SGLT2 inhibitors as a class effect reduce plasma glucose concentration by enhancing glycosuria and reduce fractional glucose reabsorption to 40%-50%. This mechanism is independent of insulin action or beta-cell function and is unique in the current armamentarium of hypoglycemic agents available in the management of diabetes. Generally, these SGLT2 inhibitors generate urinary glucose loss of 40-80 g/day and average reduction in HbA1c of 0.7%-0.9%. Chronic SGLT2 inhibition leads to cumulative negative energy balance and causes an average weight loss of 2-3 kg.

Also, SGLT2 inhibition augments osmotic diuresis by increasing filtered glucose load and impairs sodium reabsorption in proximal tubule. This diuretic effect contributes to the weight loss by a modest reduction in extracellular volume and reduction in systolic BP by 3-5 mmHg. Data from animal models suggest that SGLT2 inhibition can also mitigate the renin–angiotensin–aldosterone response to hyperglycemia, which is implicated in hypertension associated with diabetes (Figure 2).

Another effect of SGLT2 inhibition is to reduce insulin resistance by alleviating glucotoxicity, which has been demonstrated with a minimum of 2 weeks of dapagliflozin treatment.

In totality, the effects of the negative energy balance, weight loss, reduction in blood pressure (BP), and edema are observed as a class effect through chronic SGLT2 inhibition. This is paradigm altering in the management of diabetes and
hypertension associated with diabetes. Currently, several large randomized CV outcome studies involving SGLT2 inhibitors are underway and will shed light on whether these favorable surrogate outcomes translate into reduction in long-term clinical event rates. The EMPA-REG OUTCOME study answers some of those questions.

The EMPA-REG trial

The EMPA-REG trial was a randomized controlled, double-blinded trial on the cardiovascular safety of the SGLT2 inhibitor empagliflozin in a cohort of patients with type 2 diabetes at high cardiovascular risk. The trial also highlighted the potential of empagliflozin to confer benefits on micro- and macrovascular outcomes. Enrolled patients were found to have at least one of the following: history of MI, evidence of multivessel coronary artery disease (CAD), single-vessel CAD with either positive stress test or recently hospitalized for unstable angina, unstable angina with CAD, history of stroke, or peripheral artery disease. The trial enrolled 7,020 patients with cardiovascular disease at 590 different sites in 42 countries; patients were randomized to empagliflozin 10 mg, 25 mg, or placebo with a median follow-up of 3.1 years. The primary composite outcome was death from cardiovascular causes, nonfatal MI, or nonfatal stroke, as analyzed in the pooled empagliflozin group vs the placebo group. The secondary composite outcome was the primary outcome plus hospitalization for unstable angina. The primary outcome occurred in 10.5% of patients in the empagliflozin group vs 12.1% of patients in the placebo group (hazard ratio [HR] 0.86, confidence interval [CI]: 0.74–0.99, P<0.001). The secondary outcome showed noninferiority in empagliflozin group. The patients taking empagliflozin also had significantly less risk of death from cardiovascular causes (3.7% vs 5.9%, HR 0.62, CI: 0.49–0.77, P<0.001), death from any cause (5.7% vs 8.3%, HR 0.68, CI: 0.57–0.82, P<0.001), and hospitalization for heart failure (2.7% vs 4.1%, HR 0.65, CI: 0.50–0.85). Interestingly, empagliflozin showed a significant benefit in cardiovascular risk factor reduction, including a reduction in weight, waist circumference, and systolic BP. In summary, empagliflozin compared to placebo reduced the risk of all-cause death (number needed to treat [NNT] = 38/3 years) and composite cardiovascular events (NNT = 63/3 years); Figure 3 illustrates the aforementioned CV benefit of empagliflozin as compared to commonly used cardiac drugs such as simvastatin and ramipril.

Figure 3 Three large CV outcome trials have increasing cardiovascular event rates as diabetes is added to high-risk patients. Notes: There is increase in the percentage of patients with hypertension in the more recent diabetes trials. 4S trial simvastatin: 182/2,221 (8.2%), placebo: 256/2,223 (11.5%) HR = 0.71 (0.59–0.85), HOPE trial ramipril: 482/4,645 (10.4%), placebo: 569/4,652 (12.2%) HR = 0.85 (0.76–0.95), EMPA-REG emp: 269 (5.7%)/2,333, placebo: 194 (8.3%)/4,687 HR = 0.68 (0.57–0.82). The number needed to treat calculations find that empagliflozin in only 3 years has a NNT that is very close to 4S that needed 5.4 years to have NNT of 30. Abbreviations: CV, cardiovascular; HR, hazard ratio; NNT, number needed to treat; HT, hypertension.
The only significant side effect was an increase in genital infections (6.4% vs 1.8%; \( P \leq 0.001 \)). The increased risk of genital infections was noted in both males (number needed to harm [NNH] = 29/3 years) and females (NNH = 14/3 years). Moreover, the incidence of urosepsis was also increased with empagliflozin (0.4% vs 0.1%).

Cardiovascular benefits and possible mechanisms related to reduced CV events with empagliflozin

SGLT2 inhibitors have been shown so far to reduce BP, aortic stiffness, calories, body weight, and blood glucose and to increase osmotic diuresis (Figure 4).

The clinical importance of nine modifiable risk factors account for \( > 90\% \) of the risk of first MI from the INTERHEART case-controlled study that enrolled 15,152 cases and 14,820 age- and sex-matched controls worldwide. Diabetes was in one of the top three risk factors for CV disease and acute MI.\(^9\) The two other major modifiable risk factors improved by SGLT2 inhibitors are hypertension and abdominal obesity.

SGLT2 inhibitors are known to reduce BP.\(^{20} \) The range of systolic BP reduction varied from 3.7 mmHg to 7.5 mmHg over four trials. Some trials have found a small improvement in BP reduction as the dose of SGLT2 inhibitors is increased.

In regard to empagliflozin, a recent meta-analysis of ten RCTs showed that a dose of 25 mg caused a reduction in systolic BP weighted mean difference (WMD) of \(-4.19\) mmHg (CI: \(-5.17\) mmHg to \(-3.20\) mmHg; \( I^2 = 32\% \)) and diastolic BP WMD of \(-1.88\) mmHg (CI: \(-2.71\) mmHg to \(-1.04\) mmHg; \( I^2 = 56\% \)) compared to placebo.\(^{21} \) These changes were similar to those found in EMPA-REG OUTCOME trial. The reduction in BP has many known cardiovascular benefits. At a basic level, myocyte contraction is the primary factor determining myocardial oxygen consumption (MVO\(_2\)). The main clinical components of MVO\(_2\) are primarily BP (wall tension), contractility, and heart rate.\(^6\) In addition, the high-risk vulnerable plaque morphology (increased lipid/necrotic core/thin fibrous cap/vascular inflammation) coupled with increased wall stress from sudden and sustained BP elevations leads to increased risk for plaque rupture (Figure 5). Reduction in BP would reduce a well-known risk factor for acute CV events.\(^{22} \) Figure 6 illustrates mortality benefit associated with BP reduction.

**Notes:** The wall stress increases stress on the diseased diabetes vascular wall leading to plaque fracture. The thin cap is not as elastic, and the stiffness of this plaque cap increases the risk for plaque rupture. In addition, the cap frequently is much thinner with a necrotic core as seen in the PROSPECT trial.\(^{23,49} \)

**Abbreviations:** BP, blood pressure; NIRS, near infrared spectroscopy; ROS, reactive oxygen species; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; OCT, optical coherence tomography; NO, nitric oxide.
Recent evidence may also indicate that empagliflozin has benefits outside the cardiovascular system. At a basic science level, empagliflozin has been found to reduce monocyte chemoattractant protein-1, intercellular adhesion molecule-1, plasminogen activator inhibitor-1, transforming growth factor-β, and connective tissue growth factor in the diabetic kidney. This suggests anti-inflammatory and antifibrotic properties to the diabetic kidney and may suggest that empagliflozin confers renal protection as well. Further translational studies would have to be performed to confirm these findings.

Heart failure and empagliflozin

Heart failure hospitalizations are a major cause of mortality and morbidity in patients with diabetes. The EMPA-REG trial found early reductions in hospitalization for heart failure in patients treated with empagliflozin (Figure 7). This very early reduction in heart failure hospitalizations may represent the benefit of a reduction in the high left ventricular end-diastolic pressure that is frequently found in hypertensive diabetic patients due to empagliflozin-mediated osmotic diuresis.

Even normotensive patients with type 2 diabetes may be affected by diastolic dysfunction, as suggested in a case–control study (N=127) of these patients of >5 years duration. Greater than 50% prevalence of asymptomatic left ventricular diastolic dysfunction was reported, despite not being hypertensive. In addition, recent large RCTs (SAVOR, EXAMINE, and TECOS) with oral hypoglycemic agents have included >80% of patients with hypertension. Greater than 90% of patients in EMPA-REG also had hypertension. Given this information, it would be reasonable to suggest that a large number of patients in the EMPA-REG trial, as well as diabetes in general, have some degree of diastolic dysfunction. The frequent relationship between hypertension and diastolic dysfunction has been well established in a number of recent studies. Based on the current literature on hypertension and diastolic dysfunction, up to 50% of patients with hypertension have evidence of diastolic dysfunction, which in turn has been linked to a tenfold increased risk of mortality. Unfortunately, there are no clear treatments for diastolic dysfunction except for symptomatic relief with diuresis and BP control, both of which empagliflozin addresses. It seems that the abnormal ventricular matrix found in the hypertensive patient is best treated with early prevention and global risk reduction.

SGLT2 inhibitors have also shown improvement in pulse pressure and aortic stiffness measured noninvasively. Widened pulse pressure is a marker for increased vascular stiffness and is associated with adverse cardiovascular outcomes. Moreover, pulse pressure predicts CV events independent of standard CV risk factors. In addition, as Franklin et al have reported in the Framingham Heart Study, the relationship between pulse pressure and coronary disease strengthens with increasing age. It is well known that diastolic dysfunction is associated with abnormal vascular stiffness. In a small study by Molttram and associates, 70 hypertensive patients with exertional dyspnea were evaluated for diastolic dysfunction and arterial compliance. Their findings indicate a significant correlation of progressive abnormal diastolic function with reduced arterial compliance. Authors concluded that arterial compliance is an independent predictor of diastolic dysfunction in patients with hypertensive heart disease. Improvement in arterial stiffness and diastolic dysfunction may play a key role in both empagliflozin’s ability to reduce CV events and hospitalizations from heart failure.
Table 2 Key points and clinical impact of empagliflozin

Outcomes vs placebo:
- Reduction in CV death (3.7% vs 5.9%, HR 0.62)
- Reduction in all-cause mortality (5.7% vs 8.3%, HR 0.68)
- Reduction in hospitalization for heart failure (2.7% vs 4.1%, HR 0.65)

Surrogate effects:
- Osmotic diuresis
- Decreases uric acid: decreases ~0.4 mg/dL

Abbreviations: CV, cardiovascular; HR, hazard ratio; HbA1c, hemoglobin A1c; WMD, weighted mean difference; HDL, high-density lipoprotein.

---

Diabetes is likely independently contributing to the increased arterial stiffness without coexisting hypertension. At the translational biology level, patients with diabetes have increased advanced glycation end product (AGE) formation. Hyperglycemia, insulin resistance, and increased glycation end products lead to the development of increased vascular stiffness. At the cellular level, microvascular disease and vascular stiffness are mediated by the interaction of receptors such as lectin-like oxidized low-density lipoprotein receptor-1 and macrophage scavenger receptors to advanced glycation end products.5,6

Weight loss and empagliflozin

In contrast to other antiglycemic agents such as sulfonylureas, which are known to cause weight gain, the SGLT2 inhibitors have been shown to cause weight loss.4 A recent meta-analysis showed that patients taking empagliflozin lost ~1.84 kg (CI: −2.30 to −1.38) when compared to placebo.21 These results were similar to what was seen in the EMPA-REG OUTCOME trial as well as meta-analysis of dapagliflozin. Canagliflozin seemed to show a slightly higher weight reduction with meta-analysis of ten RCTs showing WMD ~2.81 kg (CI: −3.26 to −2.37).35 A recent trial comparing glimepiride and canagliflozin used X-ray absorptiometry scans to determine the etiology of weight change. It was found that about two-thirds of the weight loss in canagliflozin was attributed to a loss in fat mass, whereas glimepiride caused increased body weight from lean body mass as well as fat.36 Given that a majority of the weight loss in SGLT2s is attributed to fat loss, this would correlate with the reduction in waist circumference of ~2 cm in patients as seen in the EMPA-REG OUTCOME trial.16,21,36–38

Conclusion

SGLT2 inhibitors, particularly empagliflozin are a revolutionary class of drugs for diabetes, which have shown CV event reduction including reduction in CV death, hospitalizations for heart failure, reduction in BP, aortic stiffness, and weight loss (Table 2). Further research is needed to clarify and validate the CV benefits of empagliflozin at the translational biology level as well as its impact on clinical medicine.

Acknowledgment

The authors want to thank Ryan Marsh for his contribution to this paper.

Disclosure

Dr Robert Chilton serves on advisory boards and research for BI, Lilly, Takada, Pfizer, and MSD. The authors report no further conflicts of interest in this work.

References


Differential cardiovascular profiles of SGLT2 inhibitors